References
- Finn OJ. Cancer vaccines: between the idea and the reality. Nature Rev Immunol. 3(8), 630–641 (2003).
- Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin. Invest. 113(11), 1515–1525 (2004).
- Malaguarnera L, Ferlito L, Imbesi RM et al. Immunosenescence: a review. Arch. GerontoL Geriatr. 32(2), 77–93 (2001).
- Effros RB. Problems and solutions to the development of vaccines in the elderly. ImmunoL Allergy Clin. North Am. 23(1), 41–55 (2003).
- Schenk D, Barbour R, Dunn W etal. Immunization with AB attenuates Alzheimer's disease-like pathology in the PDAPP mouse. Nature 400(6740), 173–177 (1999).
- Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid-B peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nature Med. 6(8), 916–919 (2000).
- Weiner HL, Lemere CA, Maron R et al. Nasal administration of amyloid-B peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. NeuroL 48(4), 567–579 (2000).
- Schenk D. Amyloid-B immunotherapy for Alzheimer's disease; the end of the beginning. Nature Rev NeuroscL 3(10), 824–828 (2002).
- Orgogozo JM, Gilman S, Dartigues JF etal. Subacute meningoencephalitis in a subset of patients with AD after A1342 immunization. Neurology 61 (1), 46–54 (2003).
- Hock C, Konietzko U, Streffer JR et al. Antibodies against amyloid-il slow cognitive decline in Alzheimer's disease. Neuron 38(4), 547–554 (2003).
- Nicoll JA, Wilkinson D, Holmes C et al Neuropathology of human Alzheimer's disease after immunization with Ail peptide: a case report. Nature Med. 9(4), 448–452 (2003).
- Eurlan R, Brambilla E, Sanvito F et al. Vaccination with Ail peptide induces autoimmune encephalomyelitis in C57/13L6 mice. Brain 126(2), 285–291 (2003).
- Munch G, Robinson SR. Potential neurotoxic inflammatory responses to Ail vaccination in humans. J Neural Transm. 109(7-8), 1081–1087 (2002).